NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANDOSTATIN (octreotide acetate) is a somatostatin analog small-molecule injectable that inhibits growth hormone, glucagon, and insulin secretion, along with suppression of multiple GI hormones. It is indicated for acromegaly, neuroendocrine tumors (carcinoid, VIPoma), and off-label use across multiple solid tumors and hematologic malignancies. The drug works by mimicking somatostatin's inhibitory effects on hormone and peptide release, providing symptomatic relief and growth inhibition.
$0.169BPart D
LOE ApproachingAs LOE approaches, the brand team will shift focus to lifecycle extension, cost optimization, and managed care retention in a declining revenue environment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
Started Jul 2014
24 enrolled
Drug Interactions
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Started Nov 2011
256 enrolled
Neuroendocrine TumorsAdvanced Cancer
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Started May 2010
43 enrolled
Neuroendocrine Carcinoma
Sandostatine® LP and Hyperinsulinism
Started May 2009
10 enrolled
Congenital Hyperinsulinism
Sandostatin for Patients With Androgen Independent Prostate Cancer
Started Jul 2007
13 enrolled
Prostate Cancer
Worked on SANDOSTATIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.